EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design

Cassius M Phogole iD, Engi Abdel-Hady Algharably iD, Eric H Decloedt iD, Catherine Anne Cluver iD, Veshni Pillay-Fuentes Lorente iD

Clinical Pharmacology & Therapeutics · 13.11.2026

DOI: 10.1002/cpt.70568 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 13.11.2026. Verfasst von Cassius M Phogole und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pre‐eclampsia is a hypertensive disorder of pregnancy affecting 3–8% of pregnancies worldwide, with no disease‐modifying therapy currently available. Drug repurposing offers a promising strategy, yet no candidate has been validated to date. Pregnancy‐associated physiological changes alter drug pharmacokinetics (PK), and pre‐eclampsia itself may further modify drug disposition, complicating dose selection and contributing to inconclusive clinical trial outcomes. A structured literature search identified six prospective or randomized controlled trials of repurposed drugs for established pre‐eclampsia: esomeprazole, omeprazole, sulfasalazine, pravastatin, recombinant antithrombin, and metformin. All drugs were well tolerated, with metformin the one to show promising clinical benefit by prolonging gestation; the remaining five drugs yielded inconclusive or null efficacy outcomes. Critically, PK sampling was conducted in only three trials, and none systematically characterized exposure–response relationships using key pre‐eclampsia biomarkers, including soluble fms‐like tyrosine kinase‐1, soluble endoglin, and placental growth factor. Further common methodological limitations included small sample sizes (12–120 participants), heterogeneous gestational age eligibility criteria, and dosing regimens extrapolated from non‐pregnant populations without pregnancy‐specific optimization. These shortcomings likely contributed to the translational gap between promising preclinical findings and positive clinical trial outcomes. Model‐informed drug development (MIDD) approaches, including physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling, optimal sampling strategies, and simulation‐based dose selection, offer a framework to improve pre‐eclampsia trial design. Future studies should integrate these approaches with biomarker‐guided exposure–response analyses and prediction of fetal exposure throughout pregnancy to enhance therapeutic development, optimize maternal–fetal safety, and accelerate the identification of effective disease‐modifying therapies for pre‐eclampsia.

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Institute for Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Germany.
  • SAMRC Preeclampsia Extramural Research Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

ORCID-Profile: Cassius M Phogole, Engi Abdel-Hady Algharably, Eric H Decloedt, Catherine Anne Cluver, Veshni Pillay-Fuentes Lorente

Zitieren

APA

Phogole, C. M., Algharably, E. A., Decloedt, E. H., Cluver, C. A., & Lorente, V. P. (2026). Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70568

Vancouver

Phogole CM, Algharably EA, Decloedt EH, Cluver CA, Lorente VP. Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70568

BibTeX
@article{Phogole2026,
  author = {Phogole, Cassius M and Algharably, Engi Abdel-Hady and Decloedt, Eric H and Cluver, Catherine Anne and Lorente, Veshni Pillay-Fuentes},
  title = {Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70568}
}
Kostenlos starten →